Document Detail


Dehydrogenation of ribitol with Gluconobacter oxydans: production and stability of L-ribulose.
MedLine Citation:
PMID:  16650498     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
l-Ribulose is an important chiral lead molecule used for the synthesis of, among others, l-ribose, a high-value rare sugar used in the preparation of antiviral drugs. These drugs--nucleoside-analogues--gain importance in the treatment of severe viral diseases, like those caused by the HIV or hepatitis virus. In this study, factors that may have an impact on l-ribulose production with Gluconobacter oxydans and on the stability of l-ribulose were investigated. A bioconversion-type process, using washed resting cells, was chosen to produce l-ribulose from ribitol. In this process, the cell production and bioconversion phase were separated. The former was first optimized and a maximum cell mass of 1.5 g CDWL(-1) could be produced. For the bioconversion phase, the aeration level of the system proved to be one of the most critical factors; a maximal production rate of 15.7 g L(-1)h(-1) or 5.9 g(g CDW)(-1)h(-1) of l-ribulose could be reached. Furthermore, resting cells were found capable of completely converting ribitol solutions of up to 300 g L(-1) within 30 h, although the kinetics indicated a rather low affinity of the dehydrogenase enzymes for the substrate.
Authors:
Cassandra De Muynck; Catarina Pereira; Wim Soetaert; Erick Vandamme
Related Documents :
2889858 - Mid to late s-phase replication of the nucleolus in lymphoid human molt-4 cells.
3653258 - Relationship between cytoplasmic ph and proliferation during exponential growth and cel...
6184208 - The analysis and interpretation of dna distributions measured by flow cytometry.
8668128 - Dominant mutant alleles of yeast protein kinase gene cdc15 suppress the lte1 defect in ...
8692048 - Chromium and other insulin sensitizers may enhance glucagon secretion: implications for...
14713958 - Specific caspase interactions and amplification are involved in selective neuronal vuln...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-05-02
Journal Detail:
Title:  Journal of biotechnology     Volume:  125     ISSN:  0168-1656     ISO Abbreviation:  J. Biotechnol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-21     Completed Date:  2006-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8411927     Medline TA:  J Biotechnol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  408-15     Citation Subset:  IM    
Affiliation:
Laboratory of Industrial Microbiology and Biocatalysis, Department of Biochemical and Microbial Technology, Ghent University, Coupure links 653, B-9000 Gent, Belgium. Cassandra.DeMuynck@UGent.be <Cassandra.DeMuynck@UGent.be>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetobacter / enzymology,  growth & development
Biomass
Carbon / supply & distribution
Cell Count
Drug Stability
Gluconobacter oxydans / enzymology*,  growth & development
Hydrogen-Ion Concentration
Models, Biological
Oxidoreductases / metabolism*,  pharmacokinetics
Oxygen / pharmacology
Pentoses / biosynthesis*,  metabolism,  pharmacokinetics
Ribitol / metabolism*,  pharmacokinetics
Sugar Alcohol Dehydrogenases / metabolism,  pharmacokinetics
Time Factors
Chemical
Reg. No./Substance:
0/Pentoses; 488-81-3/Ribitol; 5556-48-9/ribulose; 7440-44-0/Carbon; 7782-44-7/Oxygen; EC 1.-/Oxidoreductases; EC 1.1.-/Sugar Alcohol Dehydrogenases; EC 1.1.1.-/L-ribose reductase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Time course analysis of tyrosine hydroxylase and angiotensinogen mRNA expression in central nervous ...
Next Document:  Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III tri...